Ventilator-Associated Pneumonia: The Role of Emerging Diagnostic Technologies

Keyphrases

• Ventilator-associated Pneumonia 100%
• Intensive Care Unit 100%
• Diagnostic Technology 100%
• Antibiotic Resistance 66%
• Antimicrobial Resistance 66%
• Broad-spectrum Antibiotics 66%
• Nosocomial Infection 66%
• Virulence 33%
• Methicillin-resistant Staphylococcus Aureus 33%
• Patient Benefit 33%
• Critically Ill Patients 33%
• Antibiotics 33%
• Bacterial Infection 33%
• Morbidity Mortality 33%
• Morbidity Costs 33%
• Pseudomonas Aeruginosa (P. aeruginosa) 33%
• Serious Infection 33%
• Gram-negative Bacteria 33%
• Acinetobacter 33%
• Rapid Diagnostic Test 33%
• Determinants of Outcome 33%
• Multidrug-resistant Bacteria 33%
• Extended-spectrum-lactamase 33%
• Resistance Emergence 33%
• Klebsiella Pneumoniae Carbapenemase 33%
• Rate of Rise 33%
• Carbapenem-resistant Enterobacteriaceae 33%
• Gram-positive Organisms 33%
• Rapid Diagnostic Technology 33%
• Vancomycin-intermediate S. Aureus 33%
• Carbapenemase-producing Bacteria 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Ventilator Associated Pneumonia 100%
• Antibiotic Agent 100%
• Infection 66%
• Hospital Infection 66%
• Antibiotic Resistance 66%
• Antimicrobial Resistance 66%
• Staphylococcus Aureus 33%
• Infectious Agent 33%
• Penicillinase 33%
• Pseudomonas aeruginosa 33%
• Gram Negative Bacterium 33%
• Bacterial Infection 33%
• Acinetobacter 33%
• Gram Positive Bacterium 33%
• Methicillin-Resistant Staphylococcus Aureus 33%
• Vancomycin 33%
• Carbapenemase 33%
• Carbapenem Resistant Enterobacteriaceae 33%
• Klebsiella pneumoniae 33%

Immunology and Microbiology

• Antimicrobial Resistance 100%
• Infectious Agent 25%
• Methicillin-Resistant Staphylococcus Aureus 25%
• Staphylococcus Aureus 25%
• Pseudomonas aeruginosa 25%
• Gram-Negative Bacteria 25%
• Gram-Positive Bacteria 25%
• Klebsiella pneumoniae 25%
• Acinetobacter 25%
• Carbapenem Resistant Enterobacteriaceae 25%